JP2008504551A - アルツハイマー病のバイオマーカー - Google Patents

アルツハイマー病のバイオマーカー Download PDF

Info

Publication number
JP2008504551A
JP2008504551A JP2007518700A JP2007518700A JP2008504551A JP 2008504551 A JP2008504551 A JP 2008504551A JP 2007518700 A JP2007518700 A JP 2007518700A JP 2007518700 A JP2007518700 A JP 2007518700A JP 2008504551 A JP2008504551 A JP 2008504551A
Authority
JP
Japan
Prior art keywords
gsk
disease
antibody
alzheimer
inactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007518700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504551A5 (enExample
Inventor
ラブストーン，サイモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Original Assignee
King's College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London filed Critical King's College London
Publication of JP2008504551A publication Critical patent/JP2008504551A/ja
Publication of JP2008504551A5 publication Critical patent/JP2008504551A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007518700A 2004-07-02 2005-07-01 アルツハイマー病のバイオマーカー Withdrawn JP2008504551A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0414894.6A GB0414894D0 (en) 2004-07-02 2004-07-02 Biomarkers of alzheimer's disease
PCT/GB2005/002592 WO2006003414A2 (en) 2004-07-02 2005-07-01 Biomarkers of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2008504551A true JP2008504551A (ja) 2008-02-14
JP2008504551A5 JP2008504551A5 (enExample) 2008-08-21

Family

ID=32843494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518700A Withdrawn JP2008504551A (ja) 2004-07-02 2005-07-01 アルツハイマー病のバイオマーカー

Country Status (9)

Country Link
US (1) US20080076140A1 (enExample)
EP (1) EP1763674A2 (enExample)
JP (1) JP2008504551A (enExample)
CN (1) CN101010589A (enExample)
AU (1) AU2005258926A1 (enExample)
BR (1) BRPI0512948A (enExample)
CA (1) CA2571692A1 (enExample)
GB (1) GB0414894D0 (enExample)
WO (1) WO2006003414A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010210610A (ja) * 2008-12-17 2010-09-24 National Tsinghua Univ 病的細胞の検出及びその利用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029503B1 (en) 2006-05-25 2013-01-02 GE Healthcare Limited 11c-labeled inhibitors of glycogen synthase kinase-3
WO2009074331A2 (en) * 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
CA2718955C (en) 2008-03-21 2015-10-13 Manuela G. Neuman Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia comprising fas-l and ck 18 as biomarkers
US20120040361A1 (en) * 2010-07-22 2012-02-16 National Tsing Hua University Methods and compositions for detection of lethal system and uses thereof
CN104237526B (zh) * 2013-06-18 2016-08-17 磁量生技股份有限公司 一种检测阿兹海默症罹患风险的系统
CA2941650A1 (en) * 2014-03-05 2015-09-11 Humanetics Corporation Predicting and reducing cognitive decline based on gsk-3 levels
CN104698188A (zh) * 2015-03-04 2015-06-10 华中科技大学 检测人血小板GSK-3β蛋白活性的斑点印迹方法
CN111323597A (zh) * 2018-12-14 2020-06-23 陈志成 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766022A4 (en) * 2004-05-07 2007-07-11 Garvan Inst Med Res DETECTION OF A DISEASE ASSOCIATED WITH BERROROUS EXPRESSION OF GLYCENE SYNTHASE KINASE 3 BETA

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010210610A (ja) * 2008-12-17 2010-09-24 National Tsinghua Univ 病的細胞の検出及びその利用

Also Published As

Publication number Publication date
CA2571692A1 (en) 2006-01-12
WO2006003414A3 (en) 2006-03-16
AU2005258926A1 (en) 2006-01-12
US20080076140A1 (en) 2008-03-27
WO2006003414A2 (en) 2006-01-12
CN101010589A (zh) 2007-08-01
BRPI0512948A (pt) 2008-04-15
GB0414894D0 (en) 2004-08-04
EP1763674A2 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
Ding et al. Loss of capillary pericytes and the blood–brain barrier in white matter in poststroke and vascular dementias and Alzheimer’s disease
Lehmann et al. Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
Li et al. Plasma α-synuclein is decreased in subjects with Parkinson's disease
Akhtar et al. Measurements of auto‐antibodies to α‐synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease
Miyajima et al. Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus
Aasly et al. Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
Chalbot et al. Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease
Ibach et al. Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample
Eller et al. α-Synuclein in Parkinson disease and other neurodegenerative disorders.
Kiđemet‐Piskač et al. Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia
Liang et al. Salivary biological biomarkers for Alzheimer’s disease
Bartosik‐Psujek et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
CN106461677B (zh) 肺高血压病的检查方法
MX2014012306A (es) Biomarcadores salivales especificos para deteccion de riesgo, diagnostico temprano, pronostico y vigilancia de las enfermedades de alzheimer y de parkinson.
Youn et al. Urine neural thread protein measurements in Alzheimer disease
Kac et al. Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
García‐Ayllón et al. Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease
Liu et al. Periphery biomarkers for objective diagnosis of cognitive decline in type 2 diabetes patients
Mukaetova-Ladinska et al. Cerebrospinal fluid biomarkers for dementia with lewy bodies
JP5914480B2 (ja) 神経変性疾患の診断方法
Rosano et al. Sex differences in Alzheimer's disease blood biomarkers in a Caribbean population of African ancestry: the Tobago Health Study
McGettigan et al. The emerging role of blood biomarkers in diagnosis and treatment of Alzheimer’s disease
Bernhardt et al. Alpha‐synuclein co‐pathology in Down syndrome‐associated Alzheimer's disease
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
CA2718955A1 (en) Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia comprising fas-l and ck 18 as biomarkers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080626

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100610